D.E. Shaw & Co
BTTX

D.E. Shaw & Co’s Better Therapeutics, Inc. Common Stock BTTX Stock Holding History

D.E. Shaw & Co’s Portfolio BTTX Stock Details BTTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-31,848
Closed -$148K – 6079
2021
Q4 		$148K Buy
+31,848
New +$261K ﹤0.01% 4972

Other funds holding BTTX

FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

D.E. Shaw & Co's BTTX Position: Q1 2022 in Review

D.E. Shaw & Co sold out of Better Therapeutics, Inc. Common Stock (BTTX) in Q1 2022, closing a stake of 31,848 shares — an estimated $148K sold.

D.E. Shaw & Co first reported a position in BTTX in Q4 2021 and held it in 1 quarter. The position peaked at $148K in Q4 2021. 14 funds tracked by Wall St. Rank hold BTTX as of Q1 2022.

  • D.E. Shaw & Co reported no remaining Better Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 31,848 Better Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $148K.
  • D.E. Shaw & Co first reported a position in Better Therapeutics, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • D.E. Shaw & Co's Better Therapeutics, Inc. Common Stock position peaked at $148K in Q4 2021.
  • 14 funds tracked by Wall St. Rank held Better Therapeutics, Inc. Common Stock as of Q1 2022.

Based on D.E. Shaw & Co's 13F filing for Q1 2022, filed 16 May 2022.